Evofem Biosciences, Inc. · OTC:EVFM
Evofem Biosciences — Investor Presentation (August 2018)
21 slides from Evofem Biosciences's investor presentation, Aug 8, 2018
Slide 1: August 2018
Exhibit 99.1 August 2018 SAUNDRA PELLETIER, CEO NASDAQ: EVFM
Slide 2: Disclaimer
Disclaimer This presentation contains forward looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. In some cases, you can identify forward looking statements by terms such as “may,” ”will,” “should,” “expect,” “plan,” “aim,”
Slide 3: Company Overview
Company Overview • Clinical-stage biopharmaceutical company • Committed to discovery, development and commercialization of innovative women’s health pharmaceuticals • Lead product candidate Amphora ® is a non-hormonal, on-demand, woman- controlled vaginal gel • Phase 3 confirmatory study in contrace
Slide 4: Leadership Headlines
Leadership Headlines “Globally experienced pharmaceutical executive with 25+ years of management experience in women’s health, raising capital, Saundra Pelletier and launching brands” Chief Executive Officer “25 years of experience in accounting and finance with over $600M in equity and debt offerin
Slide 5: Lead Asset: Amphora Vaginal Contraceptive Gel
Lead Asset: Amphora Vaginal Contraceptive Gel Body pH Level 5 Water pH Level 7 Semen/Blood pH Level 7.1 – 8 Soap pH Level 7 – 14 pH Levels 0 1 2 3 4 5 6 7 8 9 10 11 12 13 Acidic Basic Amphora - Normal Vaginal pH Level 3.5 – 4.5 5
Slide 6: Amphora: Attributes and Mechanism of Action
Amphora: Attributes and Mechanism of Action • L-lactic acid, citric acid, and potassium bitartrate • Buffering properties keep the vaginal environment in the pH acidic range • Maintains acidic vaginal environment, preventing the survival of spermatozoa • The introduction of semen into the vagina rai
Slide 7: AMP-002: Confirmatory Phase 3 Trial
AMP-002: Confirmatory Phase 3 Trial • Single-arm, open label trial in 1,400 women age 18-35 at 112 U.S. sites • Enrollment completed in February 2018 • 5 gram dose of Amphora administered up to one hour before intercourse • Primary endpoint: contraceptive efficacy over seven cycles • Exploratory end
Slide 8: Amphora is Poised to Expand the Women's Healthcare (WHC) Market
Amphora is Poised to Expand the Women’s Healthcare (WHC) Market Hormone-free On-demand & woman-controlled Easy to self-administer Bioadhesive No weight restrictions / BMI agnostic Personal lubricant properties Patent protection through 2033* *Patent pending 8
Slide 9: User Experience Satisfaction Survey
1 User Experience Satisfaction Survey • Greater than 80% of women, and their partners, rated their Amphora experiences as satisfying or extremely satisfying • Note – more than half of respondents rated their experience as “extremely satisfied” • More than 4 out of 5 those who completed the study wou
Slide 10: 16.5M Women in the U.S. Currently are Sexually Active but do Nothing to Prevent Pregnancy
16.5M Women in the U.S. Currently are Sexually Active but do Nothing to Prevent Pregnancy Amphora Targets in U.S. Women 15-44 (in Millions)1 Condoms 6M Sexually active, not using Withdrawal Method contraception 1.9M 16.5M Rhythm Method 0.7M Source: 1. Derived from NCHS Data Brief No. 173_December 20
Slide 11: Amphora Consumer Segmentation
Amphora Consumer Segmentation: Market research supports a shift in women’s attitudes towards a non-hormonal option Alternatives Supplementers Jessica* Nicole* Amanda* Laura* “Relationship Life Stage “Focused on School” “Family Focused” “Focused on Career” Focused” Age 26 35 28 45 Director of Global
Slide 12: Amphora Healthcare Providers Segmentation
Amphora Healthcare Providers Segmentation: A more effective way to predict future prescribing patterns We believe the healthcare provider community applicable to Amphora breaks down as follows: Segment A (31%) Segment B (27%)Segment C (13%) Segment D (11%) Segment E (9%) Segment F (9%) Name Attentiv
Slide 13: Direct Sales Opportunity
Direct Sales Opportunity 1 85 Sales Representatives cover ~96% of Deciles 6-10 oral contraceptive prescriptions • Optimize deciles 6-10 OB/GYN coverage at the prescribed reach and frequency • 98% of total prescriptions of the top 10K writers in the oral contraceptive 2 marketplace come from OB/GYNs
Slide 14: Precise Targeting thru Direct-to-Consumer Digital Marketing
Precise Targeting thru Direct-to-Consumer Digital Marketing Strategy • Initiate direct-to-consumer (DTC) 6-9 months post launch • Shape the Amphora market by creating awareness and excitement among women who need and desire non-hormonal contraception • Annual DTC Budget ~$25-30M PaidSearch PaidAds P
Slide 15: Pipeline: Targeting Unmet Needs in Women's Healthcare
Pipeline: Targeting Unmet Needs in Women’s Healthcare Sources: 1. Guttmacher Institute. Contraceptive Use in the United States. Available at: https://www.guttmacher.org/article/2017/10/contraceptive-method-use-united- states-trends-and-characteristics-between-2008-2012. Accessed 01 April 2018. 2. CD
Slide 16: Amphora Label Expansion Opportunity: Prevention of Chlamydia
Amphora Label Expansion Opportunity: Prevention of Chlamydia 1 • 1.6M new cases of chlamydia in 2016 in U.S. • Phase 2b trial – enrollment ongoing • Double-blinded, placebo-controlled efficacy trial at up to 50 U.S. sites • 844 women, 18-45 years old, with chlamydia infection in past four months • F
Slide 17: Pipeline Development: Prevention of Recurrent Bacterial Vaginosis (BV)
Pipeline Development: Prevention of Recurrent Bacterial Vaginosis (BV) • BV is caused by an imbalance of a woman’s vaginal bacteria • Symptoms include unpleasant odor and abnormal vaginal discharge 1 • BV has up to 58% recurrence rate • Phase 1 dose-finding study completed • pH levels maintained to
Slide 18: Key Stock Data
Key Stock Data Ticker NASDAQ: EVFM Shares outstanding 25.8M (as of 07/30/2018) Common stock warrants outstanding: Merger-related 2.0M @ $8.35 May 2018 offering 1.7M @ $7.50 Unrestricted Cash $22.8M (as of 6/30/2018) 18
Slide 19: Multiple Near-Term Catalysts
Multiple Near-Term Catalysts Initiate Phase 2b Amphora STI trial (first patient in) Dec 2017 FDA grants Fast Track designation to Amphora for the Feb 2018 prevention of urogenital chlamydia in women Complete enrollment in Phase 3 Amphora contraceptive trial Feb 2018 Last patient last visit in Phase
Slide 20: Evofem Biosciences Highlights
Evofem Biosciences Highlights Amphora is first in class, non-hormonal, on-demand Innovation • Commercial launch anticipated January 2020 Expertise World class executive leadership team Unmet Need 16.5M women feel the trade-off avoiding hormones is worth the increased risk of pregnancy Segmentation a
Slide 21: E¥OFEM
E¥OFEM BIO S.C°RVE,N C E S™
Evofem Biosciences — Investor Presentation (August 2018) on 6ix